Mirati Therapeutics, in collaboration with Monoceros Biosystems and leading academic instituations, published a novel Cancer Discovery article entitled “MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer“
